Rocket Pharmaceuticals, Inc.
$3.19 -$0.09 (-2.74%) 1D After hours
Rocket Pharmaceuticals, Inc.
Key Metrics
The Story So Far
LAST 6 MONTHS PRIMARY SOURCES ONLY-
Jul 16
Money rotated out of high-beta cohorts market-wide.
High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.
RECEIPT: ROTATION GAUGE, LIVE -
Jun 10
From its Mar 10 high, the share price fell 51%.
Peak close $5.30 on Mar 10; trough close $2.60 on Jun 10. The drawdown is the fact — the chapters around it are the context.
RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -51% -
Mar 27
The stock moved -19.6% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Mar 27 -
Mar 9
The stock moved +15.9% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Mar 9
The story updates itself as events post · The wolf reports; you decide
Snapshot
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases.
Wolf Grade COMING SOON
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.